Literature DB >> 15208207

Combining longitudinal studies of PSA.

Lurdes Y T Inoue1, Ruth Etzioni, Elizabeth H Slate, Christopher Morrell, David F Penson.   

Abstract

Prostate-specific antigen (PSA) is a biomarker commonly used to screen for prostate cancer. Several studies have examined PSA growth rates prior to prostate cancer diagnosis. However, the resulting estimates are highly variable. In this article we propose a non-linear Bayesian hierarchical model to combine longitudinal data on PSA growth from three different studies. Our model enables novel investigations into patterns of PSA growth that were previously impossible due to sample size limitations. The goals of our analysis are twofold: first, to characterize growth rates of PSA accounting for differences when combining data from different studies; second, to investigate the impact of clinical covariates such as advanced disease and unfavorable histology on PSA growth rates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15208207     DOI: 10.1093/biostatistics/5.3.483

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  11 in total

1.  Deriving benefit of early detection from biomarker-based prognostic models.

Authors:  L Y T Inoue; R Gulati; C Yu; M W Kattan; R Etzioni
Journal:  Biostatistics       Date:  2012-06-22       Impact factor: 5.899

2.  Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.

Authors:  Anna E Kettermann; Luigi Ferrucci; Bruce J Trock; E Jeffrey Metter; Stacy Loeb; H Ballentine Carter
Journal:  BJU Int       Date:  2010-11       Impact factor: 5.588

Review 3.  Prostate Cancer Screening.

Authors:  William J Catalona
Journal:  Med Clin North Am       Date:  2018-03       Impact factor: 5.456

4.  Fused lasso with the adaptation of parameter ordering in combining multiple studies with repeated measurements.

Authors:  Fei Wang; Lu Wang; Peter X-K Song
Journal:  Biometrics       Date:  2016-02-22       Impact factor: 2.571

5.  Modeling Disease Progression with Longitudinal Markers.

Authors:  Lurdes Y T Inoue; Ruth Etzioni; Christopher Morrell; Peter Müller
Journal:  J Am Stat Assoc       Date:  2008       Impact factor: 5.033

6.  What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models.

Authors:  Roman Gulati; Elisabeth M Wever; Alex Tsodikov; David F Penson; Lurdes Y T Inoue; Jeffrey Katcher; Shih-Yuan Lee; Eveline A M Heijnsdijk; Gerrit Draisma; Harry J de Koning; Ruth Etzioni
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-05       Impact factor: 4.254

7.  The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Azza Shoaibi; Gowtham A Rao; Bo Cai; John Rawl; James R Hébert
Journal:  Ann Epidemiol       Date:  2015-10-28       Impact factor: 3.797

8.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Authors:  Gerrit Draisma; Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Elisabeth Wever; Roman Gulati; Eric Feuer; Harry de Koning
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

9.  Semiparametric Bayesian classification with longitudinal markers.

Authors:  Rolando De la Cruz-Mesía; Fernando A Quintana; Peter Müller
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2007-03       Impact factor: 1.864

10.  Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.

Authors:  Kate Tilling; Hans Garmo; Chris Metcalfe; Lars Holmberg; Freddie C Hamdy; David E Neal; Jan Adolfsson; Richard M Martin; Michael Davis; Katja Fall; J Athene Lane; Hans-Olaf Adami; Anna Bill-Axelson; Jan-Eric Johansson; Jenny L Donovan
Journal:  Eur Urol       Date:  2009-03-13       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.